



[Signature]
PATENT
247/164

Box Patent Application
Assistant Commissioner for Patents
Washington, D.C. 20231

[Signature]
jc511 U.S. PTO
09/433418
11/04/99

**NEW APPLICATION TRANSMITTAL
UTILITY**

Sir:

Transmitted herewith for filing is a **utility** patent application:

Inventor(s): Joel B. Epstein

Title: TOPICAL AZATHIOPRINE FOR THE TREATMENT OF ORAL
AUTOIMMUNE DISEASES

I. PAPERS ENCLOSED HEREWITH FOR FILING UNDER 37 CFR § 1.53(b):

25 Page(s) of Written Description
5 Page(s) Claims
1 Page(s) Abstract
6 Sheets of Drawings Informal X Formal

II. ADDITIONAL PAPERS ENCLOSED IN CONNECTION WITH THIS FILING:

Declaration
 Power of Attorney: Separate or Combined with Declaration
 Assignment to _____ and assignment cover sheet
 Verified Statement establishing "**Small Entity**" under 37 CFR §§ 1.9 and 1.27

WP-5501.1

CERTIFICATE OF MAILING
(37 C.F.R. §1.10)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as 'Express Mail Post Office To Addressee' in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

EL419876356US
Express Mail Label No.

November 04, 1999
Date of Deposit

Shawn Poindexter
Name of Person Mailing Paper
Shawn Poindexter
Signature of Person Mailing Paper

Priority Document No(s): _____

Information Disclosure Statement w/PTO 1449 Copy of Citations

Preliminary Amendment

Return Postcard

III. THE FILING FEE HAS BEEN CALCULATED AS SHOWN BELOW:

BASIC FILING FEE:							\$760.00
Total Claims	36	-	20	=	16	x \$18.00	\$288.00
Independent Claims	2	-	3	=	0	x \$78.00	\$0.00
Multiple Dependent Claims	\$260	(if applicable)				<input type="checkbox"/>	\$0.00
TOTAL OF ABOVE CALCULATIONS							\$1,048.00
Reduction by ½ for Filing by Small Entity. Note 37 CFR §§ 1.9, 1.27, 1.28. If applicable, Verified Statement must be attached.							<input checked="" type="checkbox"/> \$524.00
Misc. Filing Fees (Recordation of Assignment -- \$40)							\$0.00
TOTAL FEES SUBMITTED HEREWITH							\$524.00

IV. METHOD OF PAYMENT OF FEES

A check in the amount of _____.

Charge Lyon & Lyon's Deposit Account No. **12-2475** in the amount of _____.

This application is being filed without fee or Declaration under 37 CFR § 1.53.

V. AUTHORIZATION to CHARGE FEES

The Commissioner is authorized to charge Lyon & Lyon's Deposit Account No. **12-2475** for the following:

37 CFR § 1.16(a), (f) or (g) – **(Filing fees)**

37 CFR § 1.16(b), (c) and (d) – **(Presentation of Extra Claims)**

37 CFR § 1.16(e) – **(Surcharge for filing the basic filing fee and/or Declaration on a date later than the filing date of the application)**

37 CFR § 1.17 – **(Any Application processing fees)**

PATENT
247/164

Credit Lyon & Lyon's Deposit Account No. **12-2475** for overpayment of fees.

Respectfully submitted,

LYON & LYON LLP

Dated: 11/4/99

633 West Fifth Street, Suite 4700
Los Angeles, California 90071-2066
(213) 489-1600

By: Charles M. Doyle
Charles M. Doyle
Reg. No. 39,175

Applicant or Patentee: Joel B. Epstein

Serial or Patent No. :

Filed or Issued:

For: TOPICAL AZATHIOPRINE FOR THE TREATMENT OF ORAL AUTOIMMUNE DISEASES

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS (37 CFR 1.9(f) AND 1.27(c)) – SMALL BUSINESS CONCERN

I hereby declare that I am

the owner of the small business concern identified below:

an official of the small business concern empowered to act on behalf of the concern identified below:

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.3-18, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under Section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third-part or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled

TOPICAL AZATHIOPRINE FOR THE TREATMENT OF ORAL AUTOIMMUNE DISEASES

by inventor(s) Joel B. Epstein

described in

the specification filed herewith

the application serial no. _____, filed _____.

patent no. _____, issued _____.

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below and no rights to the invention are held by any person, other than the inventor, who could not qualify as an independent inventor under 37 CFR 1.9(c) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27).

NAME ORAL SOLUTIONS, INC.ADDRESS 787 Seventh Ave., 48th Floor, New York, NY 10019 Individual Small Business Concern Nonprofit Organization

NAME _____

ADDRESS _____

 Individual Small Business Concern Nonprofit Organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small business entity is no longer appropriate. (37 CFR 1.28(b)).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING Michael FerrariTITLE OF PERSON SIGNING PresidentADDRESS OF PERSON SIGNING 787 Seventh Ave., 48th Floor, New York, NY 10019SIGNATURE Michael FerrariDATE 11/3/99

TOPICAL AZATHIOPRINE FOR THE TREATMENT OF ORAL AUTOIMMUNE DISEASES

5 This application claims priority to U.S. Provisional Application No. 60/148,804, filed on August 13, 1999.

FIELD OF THE INVENTION

The present invention relates to a method for treating persistent symptomatic oral autoimmune diseases through the use of topical azathioprine (“AZA”) or a derivative thereof. More particularly, the present invention relates to a method wherein an AZA solution or suspension is used to topically treat areas of oral tissue inflammation and ulceration caused by the onset of an oral autoimmune disease. The method of the present invention may also be performed prophylactically, to inhibit development of symptoms associated with the onset of an oral autoimmune disease. The method is described with particular reference to oral chronic graft-versus-host disease (“GVHD”).

BACKGROUND OF THE INVENTION

Autoimmune diseases occur when the body’s immune defenses overcome the normal tolerance mechanisms and attack the body’s cells, organs and systems. 20 Autoimmune diseases may be caused by an exogenous factor, or may arise spontaneously. Autoimmune diseases include a broad range of conditions that may be organ-specific or general. Among the organ-specific autoimmune disorders are

rheumatoid arthritis and pemphigoid. Among the general autoimmune disorders are system lupus erythematosus and graft-versus-host disease (“GVHD”).

A number of autoimmune disorders produce oral symptoms. These include oral lupus, oral lichen planus [12], pemphigus vulgaris [24], oral aphthous stomatitis [14], 5 pemphigoid [25], and GVHD [1,2,3]. In addition, there are immune consequences associated with acquired immune deficiency syndrome (AIDS), such as mucosal lichenoid changes and aphthae. These diseases are characterized by aberrant infiltration and activation by cells of the immune system, and exhibit various oral symptoms, including mucous membrane lesions, blisters, and erosions.

10 Oral lichen planus is a relatively common disease that can result in severe or chronic lesions involving mucosal surfaces, including the mouth [28]. These lesions can be very painful and persistent, lasting on the order of years. Oral lichen planus is often self-limiting; however, where treatment is required, systemic or intra-lesional steroid treatments are helpful. Topical steroids are only partially effective, and can lead to 15 significant side-effects.

15 Pemphigus vulgaris is a mucocutaneous disease that often involves oral lesions. The distinctive symptom is blistering between certain layers of the epidermis. The blisters may be very painful and, if left untreated, may result in sepsis, cachexia, and major fluid and electrolyte imbalances reminiscent of those seen in severe burn patients 20 [28]. Current treatment involves high doses of systemic corticosteroids and/or immunosuppressants, and because of the side-effects associated with these drugs hospitalization is often necessary.

Pemphigoid is divided into two forms – bullous pemphigoid and cicatricial pemphigoid. Of the two, cicatricial pemphigoid far more often involves oral lesions than bullous pemphigoid. Oral lesions are common in cicatricial pemphigoid, occurring in approximately 90 % of cases [25]. Chronic mucosal lesions often lead to scarring, and 5 ocular lesions may lead to blindness [28]. Treatment requires high levels of systemic corticosteroids and immunosuppressants, but even when given over long periods of time such treatments may be only partially effective.

Oral aphthous ulceration (“canker sores”) is a condition characterized by inflammatory lesions that occur principally in the mouth, although it can affect any mucosal surface. Although the cause is unknown, it has been postulated that that an 10 autoimmune antigen-antibody reaction occurs [14]. Present treatment includes oral anaesthetics, improved hygiene and occasionally oral suspensions of tetracyclines and systemic and/or topical steroids [28].

Bone marrow transplantation (“BMT”) is a common treatment for many 15 hematologic malignancies and immune deficiency states. BMT is used with increasing frequency for salvage therapy of many solid malignancies. Between 12,000 and 15,000 bone marrow transplants are performed each year in the United States. Of these, the number of allogeneic (donor) transplantations is estimated to be between 5,500 and 20 7,500. GVHD is a major complication of allogeneic BMT, occurring in 25% to 70% of BMT patients, despite GVHD prophylaxis [1].

GVHD occurs when genetically disparate but immunologically active lymphoid cells (T-cells) are transplanted into an immunosuppressed recipient incapable of rejecting the graft. The transplanted T-lymphocytes recognize histocompatibility antigens of host

tissues as foreign, become sensitized, proliferate, and directly or through secondary mechanisms attack recipient tissue. The primary target organs of GVHD are the skin, gastrointestinal tract, and liver. GVHD can occur as a result of organ transplantation or bone marrow transplantation.

5 Two forms of GVHD, acute and chronic, have been described and differ in their onset and their clinical features. Acute GVHD (aGVHD) occurs in the first 100 days post-BMT, with the median day of onset being 19 days post-transplant. The target organs of aGVHD include the skin, gastrointestinal tract, and the liver. In contrast, chronic (cGVHD) presents a far more varied multiorgan “autoimmunity” clinical picture that

10 includes liver dysfunction, pulmonary fibrosis, sclerodermatous skin changes, oral and gastrointestinal mucosa changes, and a reduced production of tears and saliva. The onset of cGVHD occurs between 100 and 400 days post-BMT. Because it involves many organs, cGVHD can cause significant morbidity and disability.

GVHD is an example of a general autoimmune disorder with oral involvement.

15 Oral findings are seen in both acute and chronic GVHD. Oral involvement ranges between 33% and 75% for patients with aGVHD and up to about 80% for those with cGVHD. In some patients, oral symptoms are the most significant clinical finding of GVHD. Oral lesions in GVHD may be lichenoid or lupus-like in appearance. Oral findings of aGVHD include painful desquamative, erythematous, and ulcerative mucosal

20 lesions [1,2]. In cGVHD, they are lichenoid with associated erythema and ulcerations; additionally, they may be associated with sicca syndrome characterized by xerostomia and progressive salivary gland atrophy [1,2,3]. Oral complications include pain due to the mucosal changes, altered or reduced taste, and may have a potential impact on

speech, deglutition, and use of oral prostheses (when present). Oral infection, particularly due to candida species, and dental demineralization and caries may also occur.

The conventional management of oral cGVHD consists of systemic
5 immuno suppressive therapies combined with proper oral hygiene and the judicious use of topical steroids [1,2]. However, for patients with oral cGVHD as the most significant clinical finding, the use of systemic immuno suppressants may result in immunosuppression of the host with attendant systemic complications. In addition, some patients experience considerable and refractory oral complications, even with maximum
10 doses of systemic immuno suppressants.

Topical formulations of some immuno suppressants, such as cyclosporin A (“CsA”), have been used in the management of various autoimmune conditions [4,5]. US Patent No. 4,996,193 to Hewitt et al. discloses formulations for the topical application of CsA to skin tissue in the treatment of autoimmune diseases, T-cell mediated immune
15 diseases, and inflammatory conditions. In addition, methods of use of these formulations, with or without accompanying systemic doses of CsA, are discussed. Topical formulations of CsA have also been employed in the management of oral cGVHD [4]. However, some GVHD patients do not respond well to systemic or topical formulations of CsA [4]. Furthermore, topical formulations of CsA are ineffective unless administered
20 at relatively high concentrations. As a result, the high cost of CsA makes the use of these methods prohibitively expensive.

The generically available drug azathioprine (“AZA”) (brand name: Imuran) is one of the most widely used cytotoxic immuno suppressants in clinical medicine. AZA is a

purine analog that is quickly metabolized *in vivo* to 6-mercaptopurine (6-MP), and thereafter to 6-thioguanine nucleotide (6-TNG). These compounds act as purine antagonists that interfere with the synthesis of DNA, RNA and protein [6]. They are known to act as immunomodulators, due to their selective effects on T cells and T cell-dependent responses [7] and their effects on natural killer cell activity [8] and humoral responsiveness [9]. AZA is commonly prescribed for many autoimmune diseases, including severe rheumatoid arthritis, systemic lupus erythematosus, myasthenia gravis, autoimmune chronic active hepatitis, and pemphigus vulgaris [10,26]. In addition, AZA is commonly prescribed to inhibit the immune responses that cause rejection of organ transplants. The role of systemic AZA in the management and prevention of inflammatory bowel disease (IBD) has been well characterized [18,19], and AZA has been shown to be efficacious in the long term management of inflammatory bowel diseases, such as Crohn's disease, with less long term toxicity than that associated with corticosteroids [19]. Systemic AZA has proven effective as a steroid-sparing immunosuppressant in the management of chronic oral vesiculocrotopathic diseases, such as pemphigus vulgaris and lichen planus [10,11,12]. AZA has been shown to be stable as a compounded liquid (50 mg/ml solution retained at least 96% of the initial concentration for 60 days at 25°C) [14], and further is much less expensive than other commonly used immunosuppressants, such as cyclosporin A.

Systemic AZA is usually administered either orally or intravenously. Oral administration is the preferred route in most cases, since the intravenous preparation is an extreme irritant. The dosage depends on the clinical requirements and the hematological tolerance of the patient, but is usually in the range of 1-4 mg/kg/day.

However, when administered systemically, AZA also induces a wide variety of significant side-effects. The side effects of systemic therapy with azathioprine [6] can be categorized as either allergic or non-allergic in nature. The allergic-type reactions appear to be dose-independent and may include the following symptoms: rash, fever, 5 pancreatitis, arthralgias, malaise, nausea, and diarrhea. The non-allergic effects are thought to be dose-dependent and include leukopenia, thrombocytopenia, hepatitis, and infection. AZA is also thought to be a mutagen and a carcinogen [26]. In light of these significant adverse effects, dosing and toxicity monitoring (including a complete blood count and liver enzyme studies) are required to monitor the patient's therapy. Weekly 10 complete blood counts are recommended for the first 8 weeks of systemic AZA treatment, and patients are monitored closely for any evidence of infection, unexpected bruising or bleeding, or other manifestations of bone marrow depression [26,27].

Recent pharmacokinetic studies of alternate formulations of azathioprine for treatment of inflammatory bowel disease (IBD) have been undertaken to provide methods 15 of local drug delivery in the lower intestine with reduced bioavailability and resultant systemic toxicity. In one study, AZA was administered as a delayed-release oral capsule and showed improved ileocolonic delivery with dramatically reduced systemic bioavailability [20]. In another study, four different formulations of AZA were compared, including intravenous, oral, delayed-release oral, and rectal foam 20 administration [21]. U.S. Patent Nos. 5,691,343 and 5,905,081 to Sandborn disclose methods for treating IBD by topical administration of AZA, using, for example, either rectal administration by an enema or oral administration of delayed release unit dosage form.

There exist only sporadic reports of the use of topical AZA in oral diseases, such as aphthous stomatitis and parodontosis [14,15], and as immunosuppressive therapy in the prevention of corneal graft rejection [16,17]. To date, the effectiveness of topical routes of AZA administration is unclear. While topical AZA was reported to have some 5 beneficial effect in the treatment of parodontosis [15], topical AZA was ineffective in the treatment of corneal graft rejections [16] and aphthous stomatitis [14]. Therefore, a need remains for an effective means to combat oral GVHD and other oral autoimmune diseases that does not implicate the serious side-effects encountered with conventional systemic AZA administration routes.

SUMMARY OF THE INVENTION

The present invention describes a method for treating oral GVHD or other oral autoimmune diseases. The method comprises administering to a patient in need of such treatment an effective amount of a topical solution or suspension of azathioprine. 10 Preferably, AZA is present in the solution or suspension at concentration of between about 0.5-50 mg/ml, and is administered at a dosage of between 50-250 mg/day. More 15 preferably, the dosage administered is between 100-200 mg/day. The patient may either rinse the oral cavity for a period of time with AZA and thereafter swallow to maintain a systemic dose or, alternatively, expectorate after rinsing with little or no swallowing of 20 the solution or suspension. AZA may be concurrently administered with a topical or systemic anti-inflammatory compound or another immunosuppressant. Furthermore, AZA may be administered prior to the onset of an autoimmune disease, to inhibit development of the symptoms associated with such a disease. For example, AZA may be

administered prior to or after a bone marrow transplant, before symptoms of either aGVHD or cGVHD develop. AZA is much less expensive than other commonly used immunosuppressants, and further may be effective in patients who do not respond to these other immunosuppressants. Furthermore, topical AZA will not promote oral 5 candidiasis, a common problem with topical steroids.

It is therefore an object of the present invention to provide a method for treating or preventing an autoimmune disease of the mouth, comprising applying to the mouth of a patient in need of such treatment an effective amount of azathioprine or a pharmaceutically acceptable salt thereof. The azathioprine is administered as often as required, and in a sufficient concentration, to provide alleviation or reduction in symptoms. The azathioprine is contacted with the surfaces of the mouth for a period of at least one minute, which allows direct contact of the drug with the afflicted areas at a higher local concentration than would be possible with systemic administration of the same drug.

BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A-1D show persisting oral GVHD in a patient prior to initiation of AZA as a topical rinse. Figure 1A: left side view of the cheek mucosal surface. Figure 1B: right side view of the cheek mucosal surface. Figure 1C: right lateral border of the tongue and tongue tip. Figure 1D: left lateral border of the tongue and tongue tip.

Figures 2A-2D show improving findings of oral GVHD associated with use of topical AZA rinse in the same patient as in Figures 1A-1D. Figure 2A: left side view of the cheek mucosal surface. Figure 2B: right side view of the cheek mucosal surface.

Figure 2C: right lateral border of the tongue and tongue tip. Figure 2D: left lateral border of the tongue and tongue tip.

Figures 3A-3D show the significantly improved oral GVHD symptoms at the last follow-up visit in June 1998 in the same patient as in Figures 1A-1D and 2A-2D. Figure 5 3A: left side view of the cheek mucosal surface. Figure 3B: right side view of the cheek mucosal surface. Figure 3C: right lateral border of the tongue and tongue tip. Figure 3D: left lateral border of the tongue and tongue tip.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention describes a method for treating oral GVHD or other oral autoimmune diseases. The method comprises administering to a patient in need of such treatment an effective amount of a topical solution or suspension of azathioprine (AZA) . An “effective amount” is an amount that when administered is effective to prevent or ameliorate the symptoms or progression of the oral autoimmune disease. The AZA may be administered alone or with a pharmaceutically acceptable carrier. The AZA may be administered in the form of an effective derivative or precursor of azathioprine, or in the form of a pharmaceutically acceptable salt of azathioprine. An effective derivative or precursor of AZA is one that, like AZA, is converted to 6-MP and thereafter to 6-TNG, or, alternatively, is a compound that is closely related structurally to AZA such that it undergoes similar biochemical reactions in the body as AZA to produce similar effects when used to treat oral autoimmune diseases or conditions. The method of the present invention may also be used to prevent or inhibit the development of

symptoms associated with an autoimmune disease, by administering to a patient an effective amount of a solution or suspension of AZA prior to the onset of such symptoms.

The term "topical solution or suspension" means a solution or suspension that can be administered to the external surface of the affected oral area. The solution or suspension may contain coloring or flavoring as needed to increase patient acceptance. It is also envisioned that the azathioprine may be administered in the form of a lozenge, lollipop, pellet, cream, gel, ointment, quick dissolving tablet, gum, mucosal adhesive, or any other solid form that will permit contact of the azathioprine with the oral mucosal surfaces. By "pharmaceutically acceptable", what is meant is that the carrier or salt is compatible with the other components of the AZA-containing solution or suspension and is not deleterious or harmful to the patient.

Those of skill in the art will appreciate that the dosage administered will vary due to a number of factors, such as, for example, the particular disease being treated; whether the treatment is therapeutic or prophylactic in nature; the pharmacodynamic characteristics of the particular agent; the duration of the topical application; the age, health, and weight of the patient; the nature and extent of the symptoms; the kind of concurrent treatment; and the effect desired. As a general rule, the amount of topical oral AZA administered will range from about 0.5 to about 50 mg/ml in the solution or suspension being used. Furthermore, a daily dosage in the range of 50-250 mg/day may be administered. Also as a general rule, the solution or suspension will be held in the mouth for at least one minute, with vigorous agitation to rinse as much of the surfaces of the oral cavity as possible. After rinsing, the solution or suspension may be expectorated, or may be swallowed to enhance the systemic concentration of azathioprine. Deviations

from these ranges that produce the therapeutic effects envisioned by the practitioner without significant harm to the patient are considered to be within the scope of the present claims. The method is simple and maximizes contact with the afflicted areas of the patient. Furthermore, AZA is much less expensive than other commonly used 5 immuno-suppressant drugs, such as cyclosporin A.

The oral topical formulation of AZA may be used either alone or in combination with a pharmaceutically acceptable systemic dose of AZA. By "in combination with", it is meant that the components are administered at the same time or sequentially in any order at different points in time. When administered at different points in time, the components should be administered sufficiently closely in time to produce the desired therapeutic effect. The systemic dose of AZA may be administered in any appropriate manner, including swallowing AZA in a solid form, such as a pill, tablet, caplet, or the like. Alternatively, the systemic AZA may be administered in the form of an oral rinse of a solution or suspension containing azathioprine. The systemic dose of azathioprine may 10 also be administered, intravenously, via a suppository, or in any other appropriate manner. In still another embodiment, the oral topical formulation of AZA may be used in combination with a pharmaceutically acceptable topical or systemic dose of an anti-inflammatory agent and/or an immuno-suppressant other than AZA. Examples of a 15 steroid anti-inflammatory agent that may be used in the method of the present invention include, without limitation, hydrocortisone, betamethasone dipropionate, betamethasone valerate, fluocinolone acetonide, triamcinolone acetonide, prednisone, methylprednisolone, or prednisolone. Examples of a nonsteroidal anti-inflammatory 20 agent include, without limitation, indomethacin, sulindac, ibuprofen, aspirin, naproxen

and tolmetin. Examples of an immunosuppressant other than AZA that may be used in the method of the present invention include, without limitation, the cyclosporins, such as cyclosporin A, cyclophosphamide, the macrolide FK-506, deoxyspergualin, thalidomide, methotrexate, bredinin, deoxyspergualin, and didemnin B. The doses of these 5 antiinflammatory agents and/or immunosuppressants are those known to the practitioner in each case to be effective without an undesirable level of adverse effects on the patient. Antiinflammatory agents and immunosuppressants other than those listed here may be used in the method of the present invention, so long as they are pharmaceutically acceptable.

10 Other oral autoimmune diseases or oral diseases with autoimmune characteristics may also be treated by the method of the present invention. Examples of such oral diseases include, without limitation, oral lichen planus, pemphigoid, pemphigus vulgaris, oral lupus, aphthous stomatitis, and lichenoid changes and aphthae associated with acquired immune deficiency syndrome (AIDS). As noted above, the oral topical 15 formulation of AZA may be used either alone or in combination with a systemic dose of AZA. In still another embodiment, the oral topical formulation of AZA may be used in combination with a topical or systemic dose of an anti-inflammatory agent and/or an immunosuppressant. The anti-inflammatory agent and/or immunosuppressant may be as listed above. Those of skill in the art will recognize that the dosages of the anti- 20 inflammatory agent and/or immunosuppressant administered for each of the diseases may vary, as described above, and that the desired dosages are those that produce the desired therapeutic effects without significant harm to the patient.

The oral rinse disclosed in the method of the present invention avoids the serious side-effects associated with systemic administration of AZA. The oral rinse method of the present invention also allows better contact of AZA with the afflicted portions of the oral cavity than might be possible using gels, creams or ointments. Furthermore, the oral 5 rinse procedure is likely to be more acceptable to patients than the use of such gels, creams, or ointments. However, such formulations may be particularly useful for the treatment of localized oral lesions. Therefore, it is intended that such formulations may also be used advantageously in the method of the present invention.

The following data further illustrate the present invention in greater detail but are 10 not intended to be construed as limiting the scope of the invention in any way.

Case Report:

We report a severe case of chronic oral GVHD refractory to systemic and topical 15 therapies, which was managed successfully with the addition of a topically applied liquid formulation of the immunosuppressive drug azathioprine (AZA).

A 34-year-old male presented with pancytopenia in late October, 1994, and was diagnosed with aplastic anemia. He received a matched sibling donor bone marrow transplant on November 1, 1994, and was seen monthly following transplant. He had continuing difficulties with GVHD, including oral involvement.

20 The patient's oral status was evaluated at day 100 post-BMT in March, 1995. Oral findings were consistent with pseudomembranous candidiasis, and an ulceration on the left cheek was consistent with minor trauma. There were no clinical findings suggestive of oral GVHD, and saliva volumes were not decreased. Acute (grade II)

GVHD (skin and liver) was treated with systemic corticosteroids. Therapy with systemic cyclosporin (3 mg/kg/b.i.d.) and prednisone (1 mg/kg/day) was commenced May, 1995.

Persisting oral problems developed, including recurrent infections (herpes simplex virus (HSV) and candida) and ulcerations secondary to GVHD, and had a major 5 negative impact on the post-BMT course. Leukoplakia involving the lateral borders of the tongue, consistent with hairy-like leukoplakia, developed. In May, 1995, he reported several days of sore mouth involving the cheeks and gums. Oral changes included findings consistent with GVHD and reactivation of HSV. HSV and candida were confirmed on culture. The clinical findings consistent with HSV improved with the 10 prescription of acyclovir. However, findings of oral GVHD persisted despite continuing systemic immunosuppressive therapy, with lichenoid changes associated with moderate erythema on the non-keratinized mucosa of the cheeks, tongue, and lips. Multiple dilated salivary ducts were visualized on the soft palate. Ulcerations of 3-4 mm in diameter were present on the lateral borders, the dorsum, and the tip of the tongue. Due to findings of 15 increasing GVHD and possible candidosis, a biopsy of the lip mucosa and minor salivary glands was completed, which demonstrated changes consistent with GVHD. Biopsy of the ulcer on the cheek was consistent with HSV.

GVHD was difficult to control despite many modifications in both systemic and topical immunosuppression. Topical corticosteroids including dexamethasone rinse (0.4 20 mg/ml), fluocinonide gel, and dermivate cream were ineffective. Topical cyclosporin preparations were ineffective (rinse) or poorly tolerated (gel). Benefit was noted with administration of high-dose systemic steroids, although this was associated with undesirable side effects (hypertension, myopathy, weight gain, and candidosis).

Intravenous immunoglobulin was added in April of 1996 because of systemic hypogammaglobulinemia. Following development of an esophageal stricture (November, 1996), Tacrolimus (FK506) was begun along with AZA tablets (100 mg/day), and cyclosporin was discontinued. The prednisone dose was maintained 5 relatively constant after November 1996 (10 mg/day). On October 24, 1997, increasing oral sensitivity associated with oral GVHD was reported. Extensive lichenoid striae with moderate erythema and ulceration involving the lateral tongue on the right and left and the right cheek was seen. A second oral biopsy of lip mucosa and minor salivary glands was completed, which was interpreted as grade II GVHD. Hydroxychloroquine was 10 added (400 mg/day) in November 1997, but was discontinued in December 1997, due to diarrhea.

In December 1997, AZA was given as a suspension (25 mg q.i.d., rinsed 1-2 minutes then swallowed to maintain the systemic dose of 100 mg/day). The AZA suspension was made by combining AZA powder with a cherry flavored methylcellulose 15 (1%) suspending vehicle to a final concentration of 5 mg/ml. The oral findings present prior to the prescription of the AZA suspension are shown in Figures 1A-1D. The oral symptoms included erythema, lichenoid striations and ulceration, moderate erythema involving the right buccal mucosa, ulceration and erythema involving the left cheek, and extensive irregular ulceration involving the left lateral border of the tongue with 20 associated intense erythema. Minor ulcerations and erythema involving the right lateral border of the tongue were also evident.

There was clinical evidence of improvement in both oral ulceration and erythema and oral sensitivity with the use of the AZA suspension (Figures 2A-2D). Lichenoid

changes were decreased, and a single ulceration measuring 5x22 mm remained on the left lateral border of the tongue, with reduction in erythema in all oral sites of involvement and resolution of oral ulcers and reduction in size of the residual ulceration on the left lateral tongue. The ulcer had thickened, rolled borders, although its central area appeared 5 to be partially re-epithelialized.

In early March, 1998, the patient stopped the AZA rinse, returning to the same dose by tablet, and within 10 days increased mouth discomfort was reported.

Examination revealed an ulceration on the left lateral border of the tongue (a 20x4 mm penetrating ulcer with 1 mm red borders, and a more anterior 5x6 mm ulcer) and a new 3 mm erosion on the right lateral border of the tongue with minimal erythema.

In April, 1998, topical AZA rinse was resumed (25 mg/ml, 5 ml t.i.d.) and the patient reported reduced oral sensitivity limited to the left lateral border of the tongue, which corresponded to a 5x15 mm superficial ulceration, with non-thickened, non-indurated margins. Patchy atrophy of the dorsal aspect of the tongue and mild lichenoid changes without erythema at sites of prior mucosal ulceration were present. Early in May 15 he reported reduced oral sensitivity, and the clinical examination revealed atrophic mucosa of the dorsal aspect of the tongue and erythema of the lateral tongue borders, with resolution of the ulceration and mild erythema present on the cheeks.

In May 1998 the patient was admitted to the hospital for pneumonia and was 20 treated with IV antibiotics. At that time, the AZA suspension was replaced with AZA tablets (continuing dose of 25 mg t.i.d.), and prednisone was increased to 20 mg/day. Examination revealed minimal erythema and lichenoid striations in the cheeks and gingiva. A 15x4 mm ulceration was present on the left lateral border of the tongue, with

clinically increased thickness of the border of the ulceration. Resumption of the AZA suspension and continuing systemic treatment was recommended. The oral ulcerations were virtually resolved at the last follow-up visit, following resumption of AZA suspension (Figures 3A-3D).

5 This case presented a number of the oral manifestations that may follow bone marrow transplantation, including oral infections (recurring candidosis and HSV-1 reactivations), hairy-leukoplakia-like changes on the tongue, altered taste that improved spontaneously after approximately 4 months following transplant; and findings of progressive systemic sclerosis [1,2,3,22,23]. Multiple early oral findings following transplant (at approximately Transplant Day +100) included taste alterations and oral sensitivity with oral ulcerations. The patient continued to have difficulty with oral GVHD, with lichenoid and lupus-like and systemic sclerosis-like manifestations. He had no difficulty with dry mouth. The case presented considerable oral involvement, including persisting ulceration of the tongue, which resulted in pain and affected the patient's quality of life. The oral symptoms and signs were improved only when systemic prednisone was increased; however, the oral ulceration on the tongue was not resolved. Various topical applications were also tried. These included topical steroids (dexamethasone rinse, fluocinonide gel, clobetasol ointment), a topical cyclosporin suspension [4], and topical cyclosporin in a mucoadhesive base (CsA in Zilactin) [5].

10 20 These approaches have been shown to improve local oral manifestations of GVHD [4,5]. However, all of these had only limited effects on the oral symptoms. An oral suspension of AZA was begun because of the persisting oral findings. No change in the systemic dose occurred, since the suspension was first introduced as a rinse and then swallowed.

During these intervals, only minimal changes were made in use of other systemic immunosuppressives, other than at the patient's last admission to the hospital due to pneumonia, when the AZA suspension was replaced with AZA tablets, and prednisone was increased (from 10 to 20 mg/day). During this time, the tongue ulcer worsened, 5 despite the increase in prednisone. Topical AZA was prescribed to maintain the systemic dosage level following discharge, when reduced doses of prednisone (10 mg/day) were provided. During periods when topical AZA was replaced with AZA by tablet, oral symptoms and signs of GVHD increased, and oral findings improved on several occasions with the resumption of topical application. When seen at last follow-up, the 10 oral ulcerative lesion had improved despite the decreased prednisone dose.

The use of a topical formulation of azathioprine theoretically offers the benefit of increasing the therapeutic local effect without the need for an increased dosage of systemic immunosuppressive agents. It is possible that the absorption of this agent via oral mucosa may increase the systemic effect in cases where systemic dosing is not provided; although, in this instance, the suspension was swallowed in order to maintain 15 the systemic dose previously administered in tablet form. The combination of agents in this case resulted in improved management of previously refractory oral GVHD, without change in systemic drugs and therefore with less risk of increased systemic side effects.

20 Additional Clinical Data:

Five other patients suffering from oral findings due to GVHD were treated with oral azathioprine solutions, using the method of the present invention. The patients were treated with 5 ml of a solution of AZA (5 mg/ml), three-four times daily. For each

treatment, the mouth was rinsed for a period of time greater than 1 minute, and then the solution was expectorated. One patient (#5) was treated once with an oral rinse, and subsequently with a combination of an AZA rinse and AZA in a gel (5 mg/ml in a 3% methylcellulose base). The patients were not treated with any systemic 5 immuno-suppressant or steroid drug. The progress of each patient was reviewed at the times indicated. The results are shown in Table 1 below.

Table 1 – Patients with GVHD

Patient #	Age	Gender	AZA Formulation	Pre-Treatment Mucositis			Post-Treatment Mucositis			F/U (weeks)	Estimated Global Improvement
				Ulcer	Erythema	Pain	Ulcer	Erythema	Pain		
1	38	F	rinse	25	4	3	0	3	0	8	75%
2	38	M	rinse	120	12	6	10	2	3	16	90%
3	35	M	rinse	80	14	6	24	7	1	24	60%
4	43	M	rinse	90	10	4	75	4	2	36	40%
5*	45	M	rinse	183	2	4	90	2	2	8	40%
5*	45	M	rinse + gel	90	2	2	65	1	1	32	50% from rinse visit

Mucositis scores:

F/U = followup

Ulcer – total ulceration all surfaces (mm²)

Erythema – total of score for all surfaces

0 = none; 1 = mild; 2 = severe

Pain – VAS 0-10 scale; 0 = no pain, 10 = most severe pain imaginable

* Patient #5 treated initially with AZA rinse formulation, and thereafter with AZA rinse + gel

10

15

All the patients demonstrated at least a 40% estimated global improvement after treatment with the method of the present invention, as compared to their condition prior to initiation of treatment. In particular, all the patients reported at least a 50 % reduction in pain, and all but one at least 50 % reduction in ulceration. The use of a combination of

an AZA rinse with a gel containing AZA also was effective in reducing the ulceration associated with oral manifestations of GVHD (Patient #5). Surprisingly, the benefits of the present invention were achieved without the requirement for maintenance of a systemic level of either immunosuppressant or steroid drugs. Thus, the side effects 5 associated with systemic administration of these drugs were avoided as well.

The method of the present invention was extended to the treatment of other conditions as well. One patient suffering from pemphigus vulgaris and one patient suffering from benign mucous membrane pemphigoid ("BMMP") were treated with the method of the present invention. The treatment procedures were as described above for 10 the additional patients with GVHD, and also included no systemic doses of immunosuppressant or steroid drugs. The results are shown in Table 2.

Table 2 - Patients with Immune Oral Conditions Other Than GVHD

Patient #	Age	Gender	Condition	AZA Formulation	Pre-Treatment Mucositis			Post-Treatment Mucositis			F/U (weeks)	Estimated Global Improvement
					Ulcer	Erythema	Pain	Ulcer	Erythema	Pain		
6	31	M	pemphigus vulgaris	rinse	230	10	7.5	150	4	2	8	60%
7	52	M	BMMP	gel	15	8	2	0	1	0	12	90%

15 BMMP – benign mucous membrane pemphigoid

In both cases shown in Table 2, a dramatic improvement was seen after treatment with the method of the present invention. In the pemphigus vulgaris patient, a 60 % reduction in Estimated Global Improvement was attained after 8 weeks of treatment with 20 an AZA rinse. In the pemphigoid case, the patient was virtually completely healed, with no ulceration or pain, and only very slight erythema, after treatment for 12 weeks. It is

noteworthy that in this latter patient, the AZA was administered in the form of a gel.

Therefore, in view of the beneficial results reported in Tables 1 and 2, AZA gel formulations, when tolerated, may represent an important alternative to the AZA rinse.

These data suggests that topical use of AZA may be an advantageous alternative
5 for management of oral immune-mediated inflammatory conditions. In particular, the oral topical delivery of AZA may be beneficial for patients with oral chronic graft-versus-host disease, and also for other autoimmune oral mucosal diseases.

The present invention has been set forth in the form of its preferred embodiments.

Other alternative embodiments may be devised, however, and are intended to be within
10 the scope of this application. Furthermore, it is intended that modifications to the disclosed invention may be made without departing from the scope and spirit of the inventive concepts set forth herein. Throughout this application various publications and patents are cited. The contents of these publications and patents are hereby incorporated by reference into the present application.

References:

1. Woo, SB, Lee, SJ, Schubert, MM. Graft-vs.-host disease. *Crit Rev Oral Biol Med* 1997; 8(2):201-216.
2. Schubert, MM, Sullivan, KM. Recognition, incidence, and management of oral graft-versus-host disease. *NCI Monogr* 1990; (9):135-143.
3. Nakamura, S, Hiroki, A, Shinohara, M, et al. Oral involvement in chronic graft-versus-host disease after allogeneic bone marrow transplantation. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 1996; 82(5):556-563.
4. Epstein JB, Reece, DE. Topical cyclosporin A for treatment of oral chronic graft-versus-host disease. *Bone Marrow Transplant* 1994; 13:81-86.
5. Epstein JB, Truelove, EL. Topical cyclosporin in a bioadhesive for treatment of oral lichenoid mucosal reactions. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 1996; 82:532-536.
6. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporin, and methotrexate. *Am J Gastroenterol* 1996; 91(3):423-433.
7. Winklestein A. The effects of azathioprine and 6-MP on immunity. *J Immunopharmacol* 1979; 1:429-454.
8. Brogan M, Hiserodt J, Oliver M, et al. The effect of 6-mercaptopurine on natural killer-cell activities in Crohn's disease. *J Clin Immunol* 1985; 5:204-11.
9. Brogan M, Stevens R, Hiserodt J, et al. Effects of 6-MP on the impaired in vivo humoral responsiveness in Crohn's disease. *Gastroenterol* 1984; 86:A1035.
10. Lozada F. Prednisone and azathioprine in the treatment of patients with vesiculocerosive oral diseases. *Oral Surg Oral Med Oral Pathol* 1981; 52(3):257-260.
11. Robinson JR, Lozada-Nur F, Frieden I. Oral pemphigus vulgaris. A review of the literature and a report on the management of 12 cases. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 1997; 84:349-355.
12. Lear, JT, English, JSC. Erosive and generalized lichen planus responsive to azathioprine. *Clin Exper Derm* 1996; 21:56-57.

5

13. Allen LV Jr, Erickson MA. Stability of acetazolamide, allopurinol, azathioprine, clonazepam, and flucytosine in extemporaneously compounded oral liquids. *Am J Health-Syst Pharm* 1996; 53:1944-1949.

10

14. Eggleston DJ, Nally FF. Treatment of aphthous ulceration with topical azathioprine. A double blind trial. *Br J Oral Surg* 1972; 9(3):233-236.

15

15. Suchko VI, Mashchenko IS. Local use of an azathioprine suspension in a dimoxide solution in the combined treatment of parodontosis. *Stomologica (Mosk)* 1981; 60(3): 28-30.

20

16. Elliot JH, Leibowitz HM. Chemotherapeutic immunosuppression of the corneal graft reaction. 3. Topical azathioprine. *Arch Ophthalmol* 1966; 76(5):709-711.

25

17. Mackay IR, Bignell JL, Smith PH, Crawford BA. Prevention of corneal-graft failure with the immunosuppressive drug azathioprine. *Lancet* 1967; 514 (2):479-482.

30

18. Choi PM, Targan SR. Immunomodulator therapy in inflammatory bowel disease. *Dig Dis Sci* 1994; 39(9):1885-1892.

35

19. Stotland BR, Lichtenstein GR. Newer treatments for inflammatory bowel disease. *Prim Care* 1996; 3(3):577-608.

40

20. Zins BJ, Sandborn WJ, McKinney JA, et al. A dose-ranging study of azathioprine pharmacokinetics after single-dose administration of a delayed-release oral formulation. *J Clin Pharmacol* 1997; 37:38-46.

21. Van Os EC, Zins WJ, Sandborn WJ, et al. Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. *Gut* 1996; 39:63-68.

22. Epstein JB, Priddy RW, Sherlock CH. Hairy leukoplakia-like lesions in immunosuppressed patients following bone marrow transplantation. *Transplantation* 1988; 46:462-4.

23. Epstein JB, Sherlock CH, Wolber RA. Hairy leukoplakia after bone marrow transplantation. *Oral Surg Oral Med Oral Pathol* 1993; 75:690-5.

24. Scully, C, Paes de Llmeida, O, Porter, SR, Gilkes, JJH. Pemphigus vulgaris: the manifestations and long-term management of 55 patients with oral lesions. *Br J Dermatol* 1999; 140:84-89.

25. Lever, WF. Pemphigus and pemphigoid. A review of the advances made since 1964. *J Amer Acad Dermatol.* 1979; 1(1):2-31.

5 26. Anstey, A, Lear, JT. Azathioprine: clinical pharmacology and current indications in autoimmune disorders. *BioDrugs* 1998; 9(1):33-47.

27. Glied, M, Rico, JM. Treatment of autoimmune blistering diseases. *Dermatol Clin* 1999; 17(2):431-330.

10 28. Sharpe et al. Method for treating diseases mediated by proteases. U.S. Patent No. 5,637,616. Issued June 10, 1997.

CLAIMS:

What is claimed is:

5 1. A method for treating an autoimmune disease of the mouth, comprising topically contacting the mouth of a patient in need of such treatment with an effective amount of a purine analog or a pharmaceutical salt thereof.

10 2. The method of Claim 1, wherein said purine analog is a member selected from the group consisting of azathioprine, 6-mercaptopurine, and 6-thioguanine nucleotide.

15 3. The method of Claim 1, wherein said purine analog is azathioprine or a derivative thereof.

20 4. The method of Claim 1, wherein said autoimmune disease of the mouth includes a member selected from the group consisting of oral lichen planus, oral aphthous stomatitis, pemphigoid, pemphigus vulgaris, oral lupus, oral graft-versus-host disease, and lichenoid changes and aphthae associated with AIDS.

25 5. The method of Claim 1, wherein said azathioprine or a pharmaceutically acceptable salt thereof is in a solution or suspension at a concentration between 0.5 and 50 mg/ml.

30 6. The method of Claim 1, wherein said azathioprine or a pharmaceutically acceptable salt thereof is administered at a dosage between 50 and 250 mg/day.

7. The method of Claim 1, wherein said azathioprine or a pharmaceutically acceptable salt thereof is administered in a solution or a suspension.

8. The method of Claim 1, wherein said azathioprine or a pharmaceutically acceptable salt thereof is administered in the form of a member selected from the group consisting of a lozenge, a lollipop, a pellet, a cream, a gel, an ointment, a quick dissolving tablet, gum, or a mucosal adhesive.

5

9. The method of Claim 1, wherein said step of topically contacting includes rinsing the mouth of said patient with said effective amount of azathioprine or a pharmaceutically acceptable salt thereof for at least one minute; and
swallowing said effective amount after said step of rinsing.

10

10. The method of Claim 1, wherein said step of topically contacting includes rinsing said mouth with said effective amount of azathioprine or a pharmaceutically acceptable salt thereof for at least one minute, and thereafter expectorating said azathioprine without swallowing.

15

11. The method of Claim 1, further comprising systemically administering an effective amount of a member selected from the group consisting of a steroidal anti-inflammatory compound, a non-steroidal anti-inflammatory compound, and an immunosuppressant.

20

12. The method of Claim 1, wherein said autoimmune disease of the mouth is oral lichen planus.

25 13. The method of Claim 1, wherein said autoimmune disease of the mouth is oral graft-versus-host disease.

14. The method of Claim 1, wherein said autoimmune disease of the mouth is pemphigoid.

15. The method of Claim 1, wherein said autoimmune disease of the mouth is pemphigus vulgaris.

16. The method of Claim 1, wherein said autoimmune disease of the mouth is
5 oral lupus.

17. The method of Claim 1, wherein said autoimmune disease of the mouth is oral aphthous stomatitis.

10 18. The method of Claim 1, wherein said autoimmune disease of the mouth is lichenoid changes and aphthae associated with acquired immune deficiency syndrome (AIDS).

15 19. A method for preventing an autoimmune disease of the mouth, comprising topically contacting the mouth of a patient in need of such treatment with an effective amount of a purine analog or a pharmaceutical salt thereof.

20 20. The method of Claim 19, wherein said purine analog is a member selected from the group consisting of azathioprine, 6-mercaptopurine, and 6-thioguanine nucleotide.

21. The method of Claim 19, wherein said purine analog is azathioprine or a derivative thereof.

25 22. The method of Claim 19, wherein said autoimmune disease of the mouth includes a member selected from the group consisting of oral lichen planus, oral aphthous stomatitis, pemphigoid, pemphigus vulgaris, oral lupus, oral graft-versus-host disease, and lichenoid changes and aphthae associated with AIDS.

23. The method of Claim 19, wherein said azathioprine or a pharmaceutically acceptable salt thereof is in a solution or suspension at a concentration between 0.5 and 50 mg/ml.

5 24. The method of Claim 19, wherein said azathioprine or a pharmaceutically acceptable salt thereof is administered at a dosage between 50 and 250 mg/day.

10 25. The method of Claim 19, wherein said azathioprine or a pharmaceutically acceptable salt thereof is administered in a solution or a suspension.

15 26. The method of Claim 19, wherein said azathioprine or a pharmaceutically acceptable salt thereof is administered in the form of a member selected from the group consisting of a lozenge, a lollipop, a pellet, a cream, a gel, an ointment, a quick dissolving tablet, gum, or a mucosal adhesive.

20 27. The method of Claim 19, wherein said step of topically contacting includes rinsing the mouth of said patient with said effective amount of azathioprine or a pharmaceutically acceptable salt thereof for at least one minute; and
swallowing said effective amount after said step of rinsing.

25 28. The method of Claim 19, wherein said step of topically contacting includes rinsing said mouth with said effective amount of azathioprine or a pharmaceutically acceptable salt thereof for at least one minute, and thereafter expectorating said azathioprine without swallowing.

30 29. The method of Claim 19, further comprising systemically administering an effective amount of a member selected from the group consisting of a steroidal anti-inflammatory compound, a non-steroidal anti-inflammatory compound, and an immunosuppressant.

30. The method of Claim 19, wherein said autoimmune disease of the mouth
is oral lichen planus.

31. The method of Claim 19, wherein said autoimmune disease of the mouth
5 is oral graft-versus-host disease.

32. The method of Claim 19, wherein said autoimmune disease of the mouth
is pemphigoid.

10 33. The method of Claim 19, wherein said autoimmune disease of the mouth
is pemphigus vulgaris.

15 34. The method of Claim 19, wherein said autoimmune disease of the mouth
is oral lupus.

35. The method of Claim 19, wherein said autoimmune disease of the mouth
is oral aphthous stomatitis.

20 36. The method of Claim 19, wherein said autoimmune disease of the mouth
is lichenoid changes and aphthae associated with acquired immune deficiency syndrome
(AIDS).

ABSTRACT

A method for treating or preventing symptoms associated with oral autoimmune diseases comprises treating a patient with an oral topical formulation of azathioprine or a pharmaceutically acceptable salt thereof. The azathioprine formulation may be used in
5 the form of an oral rinse to topically treat areas of oral tissue inflammation and ulceration caused by the onset of oral autoimmune diseases, such as GVHD. The oral topical formulation of azathioprine may also be used in combination with other topical or systemic immunosuppressants or anti-inflammatory drugs.




FIG. 1A



FIG. 1B




FIG. 1C



FIG. 1D



FIG. 2A



FIG. 2B



FIG. 2C



FIG. 2D



FIG. 3A



• FIG. 3B



Fig. 3C



Fig. 3D